1 |
ClinicalTrials.gov (NCT03933761) Pamiparib in Fusion Positive, Reversion Negative High Grade Serous Ovarian Cancer or Carcinosarcoma With BRCA1/2 Gene Mutations If Progression on Substrate Poly ADP Ribose Polymerase Inhibitbor (PARPI) or Chemotherapy (PRECISE). U.S. National Institutes of Health.
|
2 |
Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
|
3 |
National Cancer Institute Drug Dictionary (drug id 769217).
|
4 |
2014 FDA drug approvals. Nat Rev Drug Discov. 2015 Feb;14(2):77-81.
|
5 |
2016 FDA drug approvals. Nat Rev Drug Discov. 2017 Feb 2;16(2):73-76.
|
6 |
2018 FDA drug approvals.Nat Rev Drug Discov. 2019 Feb;18(2):85-89.
|
7 |
Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
|
8 |
Failure of iniparib to inhibit poly(ADP-Ribose) polymerase in vitro. Clin Cancer Res. 2012 Mar 15;18(6):1655-62.
|
9 |
Therapeutic injection of PARP inhibitor INO-1001 preserves cardiac function in porcine myocardial ischemia and reperfusion without reducing infarct size. Shock. 2010 May;33(5):507-12.
|
10 |
BGP-15, a PARP-inhibitor, prevents imatinib-induced cardiotoxicity by activating Akt and suppressing JNK and p38 MAP kinases. Mol Cell Biochem. 2012 Jun;365(1-2):129-37.
|
11 |
Design and development of a tankyrase inhibitor STP06-1002 as an anticancer therapeutic agent. Cancer Res 2017;77(13 Suppl):Abstract nr 5171.
|
|
|
|
|
|
|